Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon May 29, 2021 11:08am
154 Views
Post# 33292451

RE:RE:RE:RE:RE:RE:RE:RE:Nothing wrong with this picture lol nothing at all

RE:RE:RE:RE:RE:RE:RE:RE:Nothing wrong with this picture lol nothing at allAristotle and AVRT as an LOI deal are new as of April 1.  We are seeing advertisements of ground breaking news on what Aristotle can do for the cancer detection population so the challenge is to convince clients to actually purchase the test via the prescription of their physican, or an AVRT physican. If enough of them do so then the quarterly reports will demonstrate success as will the sp - its that simple - if not, the reverse will happen. We also may need to wait until the end of June when the deal closes to witness actual traction as that integration with CARE needs legal finalization before CARE can market the complete package including Aristotle.  In the interim, Tripp marketing of Aristotle via Linkedin, Twitter, Facebook, Investor Tel etc. is intended to get knowledge of the science out there, however, again, in the end we need sales or its all for nought as clearly, thats all investors care about. 

TSX,OTC or NAS are just trading vehicles to present stocks to investors - ultimately the product has to demonstrate its utility and non invasive uniqueness to the public via buy in - and there wont be any breakout on any of these exchanges until that breakthrough happens. Right now at a declining .56 cents on low volume, its pretty clear that investors, outside of the longs on SH, dont have a high degree of faith that Aristotle and AVRT will be successful.  Lets hope the upcoming marketing effort turns the momentum around .



e=RelevantStock]Well they need to be at a stock price of 4$ to uplist on the nasdaq.  Their guess is probably they can have a breakout on the OTCQB more easily than here on the tsx, they cannot drive the SP up despite any good news.  So they think they can reach 2$, I think it's doable.  But we have seen that it doesn't always go according to the plan here!  I am not sure what good news lthey rely on, but I don't think that the OC acquisition is a bigger news than Aristotle / AVRT, and we got crushed by shorts who took advantage of the uncertainty of the launch.[/quote]

<< Previous
Bullboard Posts
Next >>